"Texas Oncology is an independent private practice with more than 500 physicians and 210 locations across the state. Meeting the oncology needs of Texans for more than 35 years, the practice includes Texas Center for Proton Therapy, Texas Breast Specialists, Texas Oncology Surgical Specialists, and Texas Center for Interventional Surgery. As a lead participant in US Oncology Research, Texas Oncology played a role in the development of more than 100 FDA-approved therapies."

During the past decade, Texas Oncology - Baylor Charles A. Sammons Cancer Center conducted 143 clinical trials. In the 10-year time frame, 143 clinical trials started and 87 clinical trials were completed, i.e. on average, 60.8% percent of trials that started reached the finish line to date. In the past 5 years, 64 clinical trials started and 45 clinical trials were completed. i.e. 70.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Texas Oncology - Baylor Charles A. Sammons Cancer Center" #1 sponsor was "Hoffmann-La Roche" with 17 trials, followed by "Novartis Pharmaceuticals" with 17 trials sponsored, "Pfizer" with 17 trials sponsored, "Eli Lilly and Company" with 13 trials sponsored and "Seagen Inc." with 13 trials sponsored. Other sponsors include 176 different institutions and companies that sponsored additional 112 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Texas Oncology - Baylor Charles A. Sammons Cancer Center" #1 collaborator was "National Cancer Institute (NCI)" with 11 trials as a collaborator, "Merck Sharp & Dohme LLC" with 10 trials as a collaborator, "Astellas Pharma Inc" with 3 trials as a collaborator, "Bristol-Myers Squibb" with 3 trials as a collaborator and "Genentech, Inc." with 3 trials as a collaborator. Other collaborators include 40 different institutions and companies that were collaborators in the rest 40 trials.

According to Clinical.Site data, the most researched conditions in "Texas Oncology - Baylor Charles A. Sammons Cancer Center" are "Breast Cancer" (37 trials), "Metastatic Breast Cancer" (18 trials), "Melanoma" (12 trials), "Colorectal Cancer" (8 trials) and "Non-small Cell Lung Cancer" (8 trials). Many other conditions were trialed in "Texas Oncology - Baylor Charles A. Sammons Cancer Center" in a lesser frequency.

Most popular intervention types in "Texas Oncology - Baylor Charles A. Sammons Cancer Center" are "Drug" (223 trials), "Biological" (29 trials), "Other" (20 trials), "Device" (4 trials) and "Combination Product" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (22 trials), "Carboplatin" (18 trials), "Paclitaxel" (18 trials), "Gemcitabine" (14 trials) and "Docetaxel" (13 trials). Other intervention names were less common.

The vast majority of trials in "Texas Oncology - Baylor Charles A. Sammons Cancer Center" are 203 trials for "All" genders, 46 trials for "Female" genders and 6 trials for "Male" genders.

Currently, there are NaN active trials in "Texas Oncology - Baylor Charles A. Sammons Cancer Center". undefined are not yet recruiting, 51 are recruiting, 60 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 105 completed trials in Texas Oncology - Baylor Charles A. Sammons Cancer Center, undefined suspended trials, and 27 terminated clinical trials to date.

Out of the total trials that were conducted in Texas Oncology - Baylor Charles A. Sammons Cancer Center, 71 "Phase 1" clinical trials were conducted, 124 "Phase 2" clinical trials and 87 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 1 trials that are defined as “Not Applicable".